trial · primary record
gemcitabine
Muscle Invasive Bladder Urothelial Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2026-08-22 |
| Primary endpoint | the radiational disease-free survival (rDFS) |
| Registry ID | NCT06257017 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:53.676Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06257017
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Gemcitabine · compound